Therapeutic Indications

Carfilzomib is indicated for:

Multiple myeloma

Irrespective of gender only Adults (18 years old or older)

Carfilzomib in combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 20-56 mg/mĀ² on two consecutive days, each week for three weeks (days 1, 2, 8, 9, 15, and 16)


Active ingredient Carfilzomib is contraindicated in the following cases:


No gender/age discrimination

It is unknown whether carfilzomib or its metabolites are excreted in human milk. Based on its pharmacological properties, a risk to the suckling child cannot be excluded. Consequently, as a precautionary measure, breast-feeding is contra-indicated during and for at least 2 days after treatment with carfilzomib.